ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025
Pioneering Clinical Investigation: Beta Defensin Expression in Patients of Squamous Cell Carcinoma of Oral Cavity as a Forward-Looking Validation for Molecular Treatment.
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human defensins are peptides coded by certain genes released as a part of immune response that act differently to tumorigenic cells according to the class. A varied cellular response has been documented in the world literature concerning the role of defensins in the cancer cell lines, though the exact role in the internal human milieu and the role specific to head and neck cancers is still understudied. This study explores the possible role of Human Beta Defensin (HBD) 1 and 3 in head and neck squamous cell carcinoma in disease progression and their potential as biomarkers/prognostic markers. Two samples, one from the cancerous tissue and one from the normal tissue margin were taken and sent for molecular analysis, viz. mRNA isolation and PCR. The fold change gene expression of HBD 1 and 3 was calculated using a housekeeping gene, and then, as per the available results, we tried to objectify the relative expression of HBD 3 and HBD 1 and its ratio. Out of the 40 samples, 26 were adequate and processed. Expression of HBD1 (DEFB1) and HBD3 (DEFB-103 A) was assessed. Normal tissues were taken as control. GADPH (Glyceraldehyde-3-Phosphate dehydrogenase) was used as an internal control. The cycle of quantification (cq) was calculated for the cases and control. A more than two-fold (2.85 times) increase in expression of HBD1 was found; however, no expression of HBD3 was shown in both cancer tissue and control tissue samples. Additional investigations with a larger sample size, encompassing the expression analysis of cancer genes at various clinico-histopathological stages, are imperative before designating them as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.